We are live on ! Find out more
PBM icon

Psyence Biomedical

2.51 USD
-0.32
11.31%
At close Updated Nov 17, 4:00 PM EST
Pre-market
After hours
2.61
+0.10
3.98%
1 day
-11.31%
5 days
-18.24%
1 month
-39.08%
3 months
-30.47%
6 months
-45.55%
Year to date
-49.7%
1 year
-86.1%
5 years
-99.97%
10 years
-99.97%
 

About: Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Employees: 12

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 100%
Negative 0%
Neutral
GlobeNewsWire
27 days ago
Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met
NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that both milestones attached to its backstop subscription commitment in Psyence Labs Ltd.
Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met
Neutral
GlobeNewsWire
1 month ago
Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program
Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
Neutral
GlobeNewsWire
1 month ago
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
Binding term sheet with PsyLabs provides Psyence BioMed's Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs' pharmaceutical-grade ibogaine, subject to a definitive agreement Binding term sheet with PsyLabs provides Psyence BioMed's Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs' pharmaceutical-grade ibogaine, subject to a definitive agreement
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
Neutral
GlobeNewsWire
1 month ago
Psyence BioMed Announces Strategic Ibogaine Investment
Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential ibogaine clinical trial in Texas for Opioid Use Disorder (OUD). Texas Ibogaine Research Corporation (TIRC), a dedicated U.S. subsidiary of Psyence BioMed, has been established for its planned ibogaine development activities in the US.
Psyence BioMed Announces Strategic Ibogaine Investment
Neutral
GlobeNewsWire
2 months ago
Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
HIGHLIGHTS Texas-based company established as dedicated U.S. vehicle for regulated ibogaine development Positioned to hold U.S. rights to PsyLabs' pharmaceutical-grade ibogaine, subject to completion of definitive licensing arrangements Designed to coordinate supply, manufacturing, regulatory and potential clinical development activities through a single U.S. entity with U.S.-based partners NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd.
Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
Neutral
GlobeNewsWire
3 months ago
Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development
Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built
Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development
Neutral
Business Wire
5 months ago
Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform
MINNEAPOLIS--(BUSINESS WIRE)--Tredium Solutions, a provider of pharmacy benefit management (PBM) technologies, has been selected to support the administration of Scripius' commercial, Medicare, and Medicaid pharmacy benefit programs. Through this collaboration, Tredium will provide its claims platform to support accurate and reliable processing for Scripius and the customers it serves. Scripius empowers health plans, health systems, and self-funded employers to better manage rising pharmacy cos.
Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform
Neutral
GlobeNewsWire
6 months ago
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives.
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
Neutral
GlobeNewsWire
6 months ago
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
Positive
Benzinga
7 months ago
PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story
Over the weekend, President Donald Trump issued an executive order aimed at speeding psychedelic drug reviews, while also backing faster ibogaine research with a reported $50 million commitment, helping ignite premarket buying across the space and lowering perceived regulatory risk for companies tied to psychedelic development.
PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story
Price charts implemented using Lightweight Charts™